ArticleEuropean journal of ophthalmology2022

Ocular adverse events following intravitreal brolucizumab for neovascular age-related macular degeneration at a single tertiary care center.

Huy V Nguyen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.